A pregnancy physiologically based pharmacokinetic (p-PBPK) model for disposition of drugs metabolized by CYP1A2, CYP2D6 and CYP3A4

被引:94
|
作者
Lu Gaohua [2 ]
Abduljalil, Khaled [2 ]
Jamei, Masoud [2 ]
Johnson, Trevor N. [2 ]
Rostami-Hodjegan, Amin [1 ,2 ]
机构
[1] Univ Manchester, Sch Pharm & Pharmaceut Sci, Manchester M13 9PT, Lancs, England
[2] Simcyp Ltd, Sheffield, S Yorkshire, England
关键词
caffeine; metoprolol; midazolam; physiologically based pharmacokinetic model; pregnancy; BLOOD-BRAIN-BARRIER; TISSUE DISTRIBUTION; COMPUTER-MODEL; CAFFEINE; WOMEN; TRANSPORTERS; METOPROLOL; POSTPARTUM; SIMULATION; MIDAZOLAM;
D O I
10.1111/j.1365-2125.2012.04363.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Aims Pregnant women are usually not part of the traditional drug development programme. Pregnancy is associated with major biological and physiological changes that alter the pharmacokinetics (PK) of drugs. Prediction of the changes to drug exposure in this group of patients may help to prevent under- or overtreatment. We have used a pregnancy physiologically based pharmacokinetic (p-PBPK) model to assess the likely impact of pregnancy on three model compounds, namely caffeine, metoprolol and midazolam, based on the knowledge of their disposition in nonpregnant women and information from in vitro studies. Methods A perfusion-limited form of a 13-compartment full-PBPK model (Simcyp (R) Simulator) was used for the nonpregnant women, and this was extended to the pregnant state by applying known changes to all model components (including the gestational related activity of specific cytochrome P450 enzymes) and through the addition of an extra compartment to represent the fetoplacental unit. The uterus and the mammary glands were grouped into the muscle compartment. The model was implemented in Matlab Simulink and validated using clinical observations. Results The p-PBPK model predicted the PK changes of three model compounds (namely caffeine, metoprolol and midazolam) for CYP1A2, CYP2D6 and CYP3A4 during pregnancy within twofold of observed values. The changes during the third trimester were predicted to be a 100% increase, a 30% decrease and a 35% decrease in the exposure of caffeine, metoprolol and midazolam, respectively, compared with the nonpregnant women. Conclusions In the absence of clinical data, the in silico prediction of PK behaviour during pregnancy can provide a valuable aid to dose adjustment in pregnant women. The performance of the model for drugs metabolized by a single enzyme to different degrees (high and low extraction) and for drugs that are eliminated by several different routes warrants further study.
引用
收藏
页码:873 / 885
页数:13
相关论文
共 50 条
  • [31] Influence of CYP3A4 and CYP2D6 inhibition on fesoterodine treatment
    Sachse, R
    Cawello, W
    Horstmann, R
    JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 44 (10): : 1186 - 1186
  • [32] Development of CYP2D6 and CYP3A4 in the first year of life
    Johnson, T. N.
    Tucker, G. T.
    Rostami-Hodjegan, A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 83 (05) : 670 - 671
  • [33] Metoclopramide is metabolized by CYP2D6 and is a reversible inhibitor, but not inactivator, of CYP2D6
    Livezey, Mara R.
    Briggs, Erran D.
    Bolles, Amanda K.
    Nagy, Leslie D.
    Fujiwara, Rina
    Furge, Laura Lowe
    XENOBIOTICA, 2014, 44 (04) : 309 - 319
  • [34] Cross-species variability in lobular geometry and cytochrome P450 hepatic zonation: insights into CYP1A2, CYP2D6, CYP2E1 and CYP3A4
    Albadry, Mohamed
    Kuettner, Jonas
    Grzegorzewski, Jan
    Dirsch, Olaf
    Kindler, Eva
    Klopfleisch, Robert
    Liska, Vaclav
    Moulisova, Vladimira
    Nickel, Sandra
    Palek, Richard
    Rosendorf, Jachym
    Saalfeld, Sylvia
    Settmacher, Utz
    Tautenhahn, Hans-Michael
    Koenig, Matthias
    Dahmen, Uta
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [35] The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapine
    Eiermann, B
    Engel, G
    Johansson, I
    Zanger, UM
    Bertilsson, L
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1997, 44 (05) : 439 - 446
  • [36] 丹参注射液对家兔体内CYP1A2、CYP2D6和CYP3A4活性的影响
    刘高峰
    甄立棉
    黄丽军
    中国临床药理学与治疗学, 2010, 15 (07) : 775 - 780
  • [37] Nanostructures of diamond, graphene oxide and graphite inhibit CYP1A2, CYP2D6 and CYP3A4 enzymes and downregulate their genes in liver cells
    Strojny, Barbara
    Sawosz, Ewa
    Grodzik, Marta
    Jaworski, Slawomir
    Szczepaniak, Jaroslaw
    Sosnowska, Malwina
    Wierzbicki, Mateusz
    Kutwin, Marta
    Orlinska, Sylwia
    Chwalibog, Andre
    INTERNATIONAL JOURNAL OF NANOMEDICINE, 2018, 13 : 8561 - 8574
  • [38] Relationships between CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4 metabolic phenotypes and genotypes in a Nicaraguan Mestizo population
    Fernando de Andrés
    Catalina Altamirano-Tinoco
    Ronald Ramírez-Roa
    Carlos F Montes-Mondragón
    Pedro Dorado
    Eva M. Peñas-Lledó
    Adrián LLerena
    The Pharmacogenomics Journal, 2021, 21 : 140 - 151
  • [39] Abemaciclib Does Not Have a Clinically Meaningful Effect on Pharmacokinetics of CYP1A2, CYP2C9, CYP2D6, and CYP3A4 Substrates in Patients with Cancer
    Turner, P. Kellie
    Hall, Stephen D.
    Chapman, Sonya C.
    Rehmel, Jessica L.
    Royalty, Jane E.
    Guo, Yingying
    Kulanthaivel, Palaniappan
    DRUG METABOLISM AND DISPOSITION, 2020, 48 (09) : 796 - 803
  • [40] ABEMACICLIB LACKS A CLINICALLY-MEANINGFUL EFFECT ON CYP1A2, CYP2C9, CYP2D6, AND CYP3A4 SUBSTRATES IN PATIENTS WITH CANCER.
    Turner, P. K.
    Hall, S. D.
    Kulanthaivel, P.
    Tate, S. C.
    Rehmel, J.
    Royalty, J.
    Guo-Avrutin, Y.
    Chiang, A. Y.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2019, 105 : S34 - S34